Esperion Therapeutics (ESPR) Set to Announce Quarterly Earnings on Tuesday

Esperion Therapeutics (NASDAQ:ESPR) will issue its quarterly earnings data before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03. The business had revenue of $32.25 million during the quarter, compared to the consensus estimate of $26.84 million. During the same quarter in the prior year, the business posted ($0.76) earnings per share. On average, analysts expect Esperion Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Esperion Therapeutics Stock Performance

NASDAQ ESPR opened at $2.08 on Monday. Esperion Therapeutics has a twelve month low of $0.70 and a twelve month high of $3.40. The stock’s 50 day moving average is $2.34 and its 200 day moving average is $2.05.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ESPR shares. Needham & Company LLC restated a “buy” rating and set a $8.00 price target on shares of Esperion Therapeutics in a research report on Wednesday, April 10th. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Monday, March 25th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $9.33.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.